132 related articles for article (PubMed ID: 35289086)
1. Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less.
Marumo A; Omori I; Tara S; Otsuka Y; Konuma R; Adachi H; Wada A; Kishida Y; Konishi T; Nagata A; Yamada Y; Nagata R; Noguchi Y; Toya T; Igarashi A; Najima Y; Kobayashi T; Yamaguchi H; Inokuchi K; Sakamaki H; Ohashi K; Doki N
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e507-e514. PubMed ID: 35289086
[TBL] [Abstract][Full Text] [Related]
2. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Ishida S; Doki N; Shingai N; Yoshioka K; Kakihana K; Sakamaki H; Ohashi K
Ann Hematol; 2016 Jun; 95(7):1145-50. PubMed ID: 27079957
[TBL] [Abstract][Full Text] [Related]
3. A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity.
Lin F; Zhang Y; Han T; Cheng Y; Mo X; Wang J; Chen Y; Wang F; Tang F; Han W; Yan C; Xu Z; Zhang X; Wang Y; Huang X; Xu L
Clin Transplant; 2022 Jan; 36(1):e14514. PubMed ID: 34655493
[TBL] [Abstract][Full Text] [Related]
4. Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.
Mori T; Koh H; Onishi Y; Kako S; Onizuka M; Kanamori H; Ozawa Y; Kato C; Iida H; Suzuki R; Ichinohe T; Kanda Y; Maeda T; Nakao S; Yamazaki H
Int J Hematol; 2016 Apr; 103(4):461-8. PubMed ID: 26910242
[TBL] [Abstract][Full Text] [Related]
5. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
6. Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia.
Arcuri LJ; Nabhan SK; Cunha R; Nichele S; Ribeiro AAF; Fernandes JF; Daudt LE; Rodrigues ALM; Arrais-Rodrigues C; Seber A; Atta EH; de Oliveira JSR; Funke VAM; Loth G; Junior LGD; Paz A; Calixto RF; Gomes AA; Araujo CES; Colturato V; Simoes BP; Hamerschlak N; Flowers ME; Pasquini R; Rocha V; Bonfim C
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2311-2317. PubMed ID: 32949751
[TBL] [Abstract][Full Text] [Related]
7. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation.
Duléry R; Mohty R; Labopin M; Sestili S; Malard F; Brissot E; Battipaglia G; Médiavilla C; Banet A; Van de Wyngaert Z; Paviglianiti A; Belhocine R; Isnard F; Lapusan S; Adaeva R; Vekhoff A; Ledraa T; Legrand O; Cohen A; Bonnin A; Ederhy S; Mohty M
JACC CardioOncol; 2021 Jun; 3(2):250-259. PubMed ID: 34396331
[TBL] [Abstract][Full Text] [Related]
8. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan.
Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Ghafoor T; Shamshad GU; Farhan M; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Satti HS; Anwer F; Ahmed P
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2375-2382. PubMed ID: 31394274
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
[TBL] [Abstract][Full Text] [Related]
10. [Allogeneic hematopoietic stem cell transplantation for patients with aplastic anemia].
Kako S
Rinsho Ketsueki; 2020; 61(9):1388-1394. PubMed ID: 33162540
[TBL] [Abstract][Full Text] [Related]
11. [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
Yu JP; Cao S; Xin N; An XM; Qi J; Ren XB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1013-8. PubMed ID: 17956681
[TBL] [Abstract][Full Text] [Related]
12. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant.
Pérez-Valencia AI; Cascos E; Carbonell-Ordeig S; Charry P; Gómez-Hernando M; Rodríguez-Lobato LG; Suárez-Lledó M; Martínez-Cibrian N; Antelo MG; Solano MT; Arcarons J; Nomdedeu M; Cid J; Lozano M; Díaz-Ricart M; Rosiñol L; Esteve J; Urbano-Ispizua Á; Carreras E; Martínez C; Fernández-Avilés F; Rovira M; Salas MQ
Blood Adv; 2023 May; 7(10):2018-2031. PubMed ID: 36453637
[TBL] [Abstract][Full Text] [Related]
14. Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies.
Zhao XF; Mao XF; Wan DM; Liu W
Transplant Proc; 2014 Jun; 46(5):1531-5. PubMed ID: 24935325
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
[TBL] [Abstract][Full Text] [Related]
16. [Hematopoietic stem cell transplantation for acquired aplastic anemia].
Yamazaki H
Rinsho Ketsueki; 2015 Oct; 56(10):2153-9. PubMed ID: 26458455
[TBL] [Abstract][Full Text] [Related]
17. Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.
Guo Z; Gao HY; Zhang TY; Liu XD; Yang K; Lou JX; He XP; Zhang Y; Chen P; Chen HR
Int J Hematol; 2016 Dec; 104(6):720-728. PubMed ID: 27709450
[TBL] [Abstract][Full Text] [Related]
18. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
Wang YH; Tien FM; Tsai CH; Huang HH; Liu JH; Liao XW; Tang JL; Yao M; Ko BS
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1488. PubMed ID: 34196132
[TBL] [Abstract][Full Text] [Related]
19. Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
Liu QF; Fan ZP; Wu MQ; Sun J; Wu XL; Xu D; Jiang QL; Zhang Y; Huang F; Wei YQ; Zhao J; Yu GP; Meng FY
Ann Hematol; 2013 May; 92(5):679-87. PubMed ID: 23274355
[TBL] [Abstract][Full Text] [Related]
20. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
